Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 29 09:38AM ET
1.66
Dollar change
-0.02
Percentage change
-1.18
%
IndexRUT P/E- EPS (ttm)-0.74 Insider Own1.54% Shs Outstand192.74M Perf Week40.69%
Market Cap319.99M Forward P/E- EPS next Y-1.67 Insider Trans-0.74% Shs Float189.78M Perf Month56.62%
Income-91.17M PEG- EPS next Q-0.65 Inst Own67.18% Short Float15.06% Perf Quarter-56.77%
Sales21.73M P/S14.73 EPS this Y43.98% Inst Trans7.50% Short Ratio2.07 Perf Half Y-55.96%
Book/sh2.08 P/B0.80 EPS next Y11.97% ROA-16.08% Short Interest28.59M Perf Year-68.07%
Cash/sh0.95 P/C1.75 EPS next 5Y45.80% ROE-47.81% 52W Range0.88 - 5.53 Perf YTD20.30%
Dividend Est.- P/FCF- EPS past 5Y15.14% ROI-20.06% 52W High-69.98% Beta0.81
Dividend TTM- Quick Ratio1.42 Sales past 5Y-29.98% Gross Margin-15.86% 52W Low88.87% ATR (14)0.15
Dividend Ex-Date- Current Ratio1.55 EPS Y/Y TTM87.79% Oper. Margin-1523.91% RSI (14)65.07 Volatility18.11% 10.67%
Employees323 Debt/Eq1.36 Sales Y/Y TTM322.60% Profit Margin-419.62% Recom2.31 Target Price5.57
Option/ShortYes / Yes LT Debt/Eq1.04 EPS Q/Q29.93% Payout- Rel Volume0.91 Prev Close1.68
Sales Surprise-8.62% EPS Surprise1.29% Sales Q/Q17353.52% EarningsNov 07 BMO Avg Volume13.78M Price1.66
SMA2047.29% SMA5023.68% SMA200-43.25% Trades Volume875,279 Change-1.18%
Date Action Analyst Rating Change Price Target Change
Dec-11-23Downgrade HSBC Securities Hold → Reduce
Dec-08-23Upgrade Morgan Stanley Underweight → Equal-Weight $3 → $7
Oct-17-23Initiated Cantor Fitzgerald Neutral
Sep-06-23Initiated HSBC Securities Buy $4.21
Jul-19-23Upgrade BofA Securities Neutral → Buy $6 → $10
Jun-01-23Upgrade Barclays Equal Weight → Overweight $7 → $8
Apr-28-23Initiated JP Morgan Overweight $7
Mar-07-23Initiated Robert W. Baird Outperform $10
Aug-05-22Upgrade Barclays Underweight → Equal Weight
Aug-02-22Upgrade Raymond James Mkt Perform → Outperform $8
Jan-27-24 07:28AM
05:27AM
Jan-10-24 06:55AM
Jan-08-24 08:00AM
Jan-04-24 03:32PM
07:15AM Loading…
Jan-03-24 07:15AM
Jan-02-24 08:00AM
Dec-26-23 08:00AM
Dec-24-23 07:39AM
Dec-23-23 07:30AM
Dec-22-23 08:45AM
Dec-20-23 02:23PM
01:54PM
Dec-19-23 09:41PM
Dec-18-23 04:01PM
11:14AM Loading…
Dec-15-23 11:14AM
Dec-11-23 05:43AM
Dec-10-23 12:02PM
Dec-09-23 11:31AM
Dec-08-23 01:45PM
01:01PM
12:35PM
Dec-07-23 11:30AM
08:45AM
Dec-01-23 07:41AM
Nov-29-23 02:28PM
Nov-26-23 04:44PM
Nov-24-23 07:00AM
Nov-08-23 03:39PM
Nov-07-23 05:18PM
08:00AM Loading…
08:00AM
07:46AM
07:27AM
07:00AM
Nov-04-23 08:45AM
Nov-02-23 09:37AM
Oct-30-23 08:00AM
Oct-24-23 08:00AM
Oct-17-23 09:47AM
Sep-29-23 09:00AM
Sep-20-23 07:21AM
Sep-12-23 07:00AM
05:14AM
Sep-07-23 11:30AM
Sep-05-23 04:05PM
Aug-29-23 05:25AM
Aug-28-23 08:30AM
Aug-24-23 10:15AM
Aug-16-23 07:00AM
Aug-08-23 08:25AM
07:18AM
07:00AM
07:00AM
Aug-05-23 09:40AM
Jul-27-23 11:19AM
Jul-25-23 08:00AM
Jul-22-23 06:14AM
Jul-20-23 01:14AM
Jul-19-23 12:36PM
Jun-30-23 10:15AM
Jun-29-23 09:53AM
07:45AM
Jun-21-23 07:00AM
Jun-15-23 10:00AM
Jun-08-23 11:30AM
Jun-01-23 02:09AM
May-10-23 07:57AM
May-09-23 07:10AM
07:00AM
Apr-27-23 04:05PM
Apr-24-23 03:49PM
07:30AM
Apr-13-23 02:17PM
Apr-06-23 10:15AM
08:00AM
06:30AM
Apr-02-23 09:15AM
Mar-30-23 01:54PM
Mar-29-23 08:15AM
07:00AM
Feb-24-23 10:00AM
Feb-08-23 08:05AM
Feb-03-23 05:00AM
Jan-30-23 09:12AM
Jan-24-23 08:58AM
Jan-22-23 09:00AM
Jan-18-23 08:00PM
09:12AM
06:43AM
Jan-09-23 07:00AM
Jan-07-23 10:07AM
Jan-06-23 07:30AM
Jan-05-23 01:13PM
08:00AM
Jan-03-23 08:00AM
Dec-28-22 12:32PM
Dec-26-22 08:00AM
Dec-24-22 08:07AM
Dec-21-22 08:54AM
Dec-19-22 01:48PM
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Vittiglio JosephChief Business & Legal OfficerFeb 05Sale0.905,2174,70844,783Feb 06 04:07 PM
Klima Thomas JSee RemarksFeb 05Sale0.902,7142,449129,413Feb 06 04:07 PM
Obenshain AndrewPresident and CEOFeb 05Sale0.901,8791,696286,093Feb 06 04:07 PM
Obenshain AndrewPresident and CEOJan 05Sale1.433,1624,520287,972Jan 09 04:05 PM
Colvin Richard AChief Medical OfficerJan 05Sale1.42597845125,138Jan 09 04:05 PM
Krawtschuk ChristopherChief Financial OfficerDec 06Sale4.524,52620,43745,474Dec 08 04:42 PM
Obenshain AndrewPresident and CEONov 03Sale3.178072,555291,134Nov 03 04:10 PM
Colvin Richard AChief Medical OfficerNov 02Sale2.982,3436,975125,735Nov 03 04:10 PM
Klima Thomas JSee RemarksSep 05Sale3.799223,493132,127Sep 06 04:30 PM
Obenshain AndrewPresident and CEOAug 10Sale3.5416,92959,956291,941Aug 10 05:00 PM
Klima Thomas JSee RemarksJun 02Sale3.504,13014,451133,049Jun 06 04:06 PM